 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Nov 20, 2017 |
| Title |
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
The estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degraders and/or aromatase inhibitors is a standard approach used in the management of this disease. Despite the positive clinical impact of these interventions, de novo and acquired resistance limits the therapeutic lifespan of these classes of drugs. Considering what is known about the complex mechanisms that contribute to the development of resistance it is likely that further development of ER-modulators will yield only incremental improvements. Thus, with the view that resistance is inevitable, we undertook the development of a new approach to treat ER-positive breast cancer by identifying and exploiting targetable vulnerabilities that emerge in endocrine therapy resistant disease. Genomic discovery platforms, including DNASeq, ChIPSeq and RNASeq were used to assess the epigenome, targeting global transcription factor binding profile, and transcriptome in cellular models of endocrine therapy sensitive and resistant disease. DNASeq was first used to identify the chromatin state, with a focus on differences, between these two models. Motif enrichment analysis indicated FOXA1 was a candidate transcription factor influencing the chromatin architecture, which was consistent with previously published studies. This led to the examination of the FOXA1 chromatin binding profile in these models. FOXA1 has previously been described to bind at enhancers. Furthermore, the relative transcription activity of specific enhancers has been shown to be indicated by the epigenomic marks on histones flanking transcription factor binding sites. For this reason, we assessed the specific pattern of histone 3 lysine 4 methylation to confirm enhancer status and histone 3 lysine 27 acetylation as an indicator of transcriptional activity. The specific patterns and distribution of FOXA1 binding was then integrated with this epigenomic information to reveal a subset of enhancers that became activated and another subset that gained enhanced activation in the tamoxifen resistant setting relative to the tamoxifen sensitive model from which it was derived. These results were integrated with the differential transcriptome, or genes shown to be differential expressed based on RNASeq, in the TAMR model as compared to its parental cell line, MCF7-WS8, and confirmed that the active enhancers were in fact associated with genes that were expressed more highly, on average, in the TAMR model. Motif enrichment at these two subgroups of enhancers indicated that another transcription factor, GRHL2, likely interacts with FOXA1 at these active sites. These results were again integrated with the “differential transcriptome” based on RNASeq and confirmed that the active enhancers, and indicated an even stronger enrichment of genes that were expressed more highly, on average, in the TAMR model relative to the MCF7-WS8 model. The GRHL2 transcriptome was then further defined by both GRHL2 ChIPSeq as well as RNASeq by comparing TAMR samples in which downregulation of GRHL2 expression had been achieved via siRNA as compared to control siRNA sequences. The collection of these data defined a subset of genes, the GRHL2 dependent transcriptome, that demonstrated increased expression in TAMR. The results of these cell lines studies were corroborated by assessing the transcriptome of xenograft mouse models of endocrine therapy sensitive and resistant disease. Integrative analysis of these data identified a collateral ER-independent signaling pathway in endocrine therapy resistant tumors that converges upon and modulates the FOXA1 and GRHL2 cistrome/transcriptome.
|
| |
|
| Overall design |
In total, 18 samples were analyzed for transcript expression profiles. This study compares depletion of GRHL2 by siRNA vs siCtrl. Independent biological triplicates and two technical replicates were used for each siRNA (siCtrl, SiGRHL2-A, siGRHL2-C).
|
| |
|
| Contributor(s) |
Jasper JS, Cocce KJ, Everett L, Wardell S, Westerling T, Krebs T, Baldi R, Wright TM, Yllanes A, Blitzer JT, Logsdon C, Rakiec D, Ruddy D, Hyslop T, Hall A, Marks JR, Crawford GE, Brown M, Mcdonnell DP |
| Citation(s) |
31644911 |
| |
| Submission date |
Nov 08, 2017 |
| Last update date |
Dec 03, 2019 |
| Contact name |
Jeff Jasper |
| Organization name |
Duke University
|
| Department |
Pharmacology and Cancer Biology
|
| Lab |
McDonnell
|
| Street address |
Box 3813
|
| City |
Durham |
| State/province |
NC |
| ZIP/Postal code |
27710 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (18)
|
|
| This SubSeries is part of SuperSeries: |
| GSE106695 |
GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer |
|
| Relations |
| BioProject |
PRJNA417694 |
| SRA |
SRP124640 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE106694_Study_genes_normalized_counts.txt.gz |
2.2 Mb |
(ftp)(http) |
TXT |
| GSE106694_Study_genes_raw_counts.txt.gz |
1.2 Mb |
(ftp)(http) |
TXT |
| GSE106694_Study_transcripts_normalized_counts.txt.gz |
7.2 Mb |
(ftp)(http) |
TXT |
| GSE106694_Study_transcripts_raw_counts.txt.gz |
3.7 Mb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...